The research team, led by Ryan Wei Kwan Wong and Thibault Mayor of the Department of Biochemistry and Molecular Biology at the Michael Smith Laboratories, set out to characterize the proteomic changes that occur when Saccharomyces cerevisiae is pushed to produce a heterologous protein. Their model target was laccase, an enzyme that is not native to yeast and therefore places distinctive demands on the cell’s protein folding and secretion machinery. By tracking protein abundance over four days of batch cultivation, the researchers were able to separate the effects of ordinary growth and nutrient depletion from the specific burden imposed by recombinant protein expression.

The scale of the survey is significant. Using quantitative mass spectrometry, the team measured the abundance of thousands of proteins across the cultivation period, capturing the ebb and flow of the cellular machinery as the culture progressed. This time-resolved approach matters because recombinant production in batch culture is not a static process: cells pass through exponential growth, nutrient exhaustion, and stress phases, and each stage imposes its own demands. A single snapshot at the end of a fermentation run would miss much of the story.

One of the clearest results is that the bulk of proteomic change during batch cultivation is driven not by the recombinant protein itself but by the shifting nutritional environment. As nutrients are depleted, a substantial portion of the proteome shifts, with ribosomal and metabolic proteins among the categories that change most noticeably. This makes biological sense: as the growth rate slows, cells downsize their protein synthesis apparatus and rewire their metabolism to survive on whatever carbon and nitrogen sources remain. Distinguishing this background remodeling from the specific response to laccase production was a central analytical challenge of the study.

When the researchers isolated the signature of laccase expression, a striking pattern emerged: only a smaller subset of proteins was specifically affected by producing the foreign enzyme. In other words, the cell does not mount a wholesale, dramatic overhaul in response to a heterologous protein. Instead, the response is comparatively targeted, involving particular classes of proteins that help the cell cope with the added biosynthetic and folding load. This finding refines the common assumption that recombinant production is a broadly destabilizing stress for the host cell.

The most consequential part of the study came from a comparison across strains. Rather than working with a single laboratory isolate, the team examined S. cerevisiae strains of different origins and with different capacities to produce active laccase. What they found was that each strain displayed a distinct proteomic response to heterologous expression, and, notably, that this individuality persisted regardless of the origin of the laccase enzyme being produced. The strain, not the foreign protein, appeared to dictate the shape of the cellular response.

Concrete examples illustrate the point. The molecular chaperones Hsp26 and Kar2 were specifically elevated in a whey-derived strain upon laccase expression. Kar2, also known as BiP, is a key chaperone of the endoplasmic reticulum, the compartment where secreted proteins fold, while Hsp26 is a cytosolic chaperone associated with stress protection. Their selective induction in one strain but not others shows that different yeast lineages deploy different quality-control strategies when confronted with the same production task. The cellular environment each strain provides is genuinely unique.

Perhaps the most provocative conclusion is that the strains with a higher capacity to produce active recombinant laccase owe their advantage not to a stronger or better-coordinated response during production, but to small groups of proteins that are constitutively expressed at different levels even before the foreign gene is switched on. In other words, the winning strains start the race with an advantage already built in. Their baseline proteome, shaped by their evolutionary history and ecological origin, happens to provide a cellular milieu that is more favorable for folding, processing, or sustaining the recombinant product.

This has practical implications for the biotechnology industry. Recombinant protein production in yeast underpins the manufacture of biopharmaceuticals, industrial enzymes, and food ingredients, and yield improvement has traditionally focused on engineering the production strain: adding gene copies, overexpressing chaperones, or optimizing promoters and secretion signals. The new results suggest a complementary and potentially underexploited strategy: screening naturally occurring yeast diversity for strains whose native proteomes are already well suited to a given product. Rather than forcing a standard laboratory strain to adapt, producers could select a strain whose inherent biology does much of the work.

The study also carries a conceptual message for the field. Because each strain responds differently to the same recombinant protein, proteomic data gathered from one background may not generalize to another, a caveat for anyone using a single reference strain to model production behavior. At the same time, the identification of constitutively expressed protein groups associated with high yields provides concrete molecular leads for future work, whether in rational engineering or in breeding programs that combine favorable natural traits. As the authors note, this is the first look at the dynamic proteome remodeling that occurs during recombinant laccase expression, and it highlights the potential of exploiting naturally occurring yeast diversity rather than relying solely on strain engineering to improve recombinant protein yields. For an organism that has served biotechnology for decades, S. cerevisiae still has surprises hidden in its wild relatives and industrial isolates, and those hidden differences may be the key to the next generation of cell biofactories.

Subject of Research: Proteomic responses of Saccharomyces cerevisiae strains during recombinant laccase production

Article Title: Alterations of the Saccharomyces cerevisiae proteome by protein production are dependent on strain origins

Article References: Wong, R. W. K., Chandhok, S., Hui, E., & Mayor, T. (2026). Alterations of the Saccharomyces cerevisiae proteome by protein production are dependent on strain origins. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14014-6

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14014-6

Keywords: Saccharomyces cerevisiae, recombinant protein production, proteomics, laccase, yeast strain diversity, chaperones, mass spectrometry, cell biofactories, heterologous expression, biotechnology, Alterations, Saccharomyces

The research, led by Eddie Guillermo Sanchez-Rueda and colleagues at the Laboratory of Biomolecular Engineering and Bionanotechnology of the Institute of Chemistry at the National Autonomous University of Mexico, focused on two well-characterized antimicrobial peptides with very different origins. The first, aurein 1.2, is a short amphipathic peptide originally described from the skin secretions of Australian tree frogs, known for disrupting bacterial membranes. The second, myxinidin, is a peptide derived from a fish pathogen, which has attracted attention for its activity against a broad range of Gram-negative bacteria. Both peptides are small, positively charged, and membrane-active, which makes them attractive drug candidates but also makes them difficult guests in a living production cell.

The team’s central design decision was to genetically fuse each peptide to a triblock polypeptide the authors call CSB, a protein-engineering scaffold that self-assembles into nanoparticles. Rather than letting the antimicrobial peptides float freely in the yeast cell, where their membrane-disrupting activity could poison the host and depress yields, the fusion strategy tethers them to a larger, structured carrier. Once the fusion proteins are produced and purified, the CSB block drives the molecules to organize themselves into discrete protein nanoparticles, effectively immobilizing the peptides within a supramolecular architecture. This kind of self-assembling carrier serves a dual purpose: it shields the producing organism during fermentation, and it creates a nanoparticle format that could later be useful for delivery or formulation of the antimicrobial cargo.

Producing the fusion proteins in Pichia pastoris required careful optimization of the fermentation conditions, and this is where much of the study’s practical value lies. Pichia is a workhorse of industrial biotechnology, prized for its ability to grow to very high cell densities and for a strong, tightly regulated promoter that responds to methanol. The researchers systematically varied the concentrations of glycerol, used as a carbon source for building biomass, and methanol, used to induce expression of the recombinant genes, along with the pH of the culture medium. The outcome of these experiments was strikingly clear: the single most important factor was allowing the yeast to accumulate extensive biomass before the methanol induction was triggered, combined with letting the medium acidify to a permissive pH of approximately 3.

Under those optimized conditions, the gains were dramatic. The aurein 1.2–CSB fusion, abbreviated Aur-CSB, increased in yield by up to 35.3-fold, reaching 35.95 plus or minus 19.05 milligrams per liter of culture. The myxinidin–CSB fusion, Myx-CSB, showed a more modest but still substantial improvement of up to 5.5-fold, reaching 12.96 plus or minus 5.75 milligrams per liter. The difference between the two constructs is itself informative, because it illustrates a familiar reality of recombinant protein production: even two peptides of similar size and function can behave very differently once fused to the same carrier, and yields must be tuned construct by construct rather than assumed from a general protocol.

After purification, the critical question was whether the fusion proteins actually did what the design intended: assemble into nanoparticles. The researchers turned to two complementary biophysical techniques to find out. Atomic force microscopy, which scans a sharp probe across a surface to map its topography with nanometer resolution, and dynamic light scattering, which infers particle size from fluctuations in scattered laser light, both confirmed self-assembly. Interestingly, the three constructs adopted different morphologies. The bare CSB polypeptide formed rod-shaped nanoparticles with an average height of 3.55 plus or minus 0.38 nanometers, while both the Aur-CSB and Myx-CSB fusions formed globular particles, with average heights of 9.79 plus or minus 1.56 nanometers and 9.28 plus or minus 0.99 nanometers respectively. The attached antimicrobial peptides thus appear to influence not just the yield but the geometry of the assembled structures.

With the nanoparticles in hand, the team moved to a preliminary test of biological function, using Escherichia coli as the target organism. Rather than relying on a single assay, they combined fluorescent probes that report on different aspects of bacterial health. A live/dead viability test based on SYTO 9 and propidium iodide staining was used to assess membrane integrity: SYTO 9 stains all cells green, while propidium iodide, which cannot cross intact membranes, only enters and stains red those cells whose membranes have been compromised. Hoechst dye was used to stain bacterial DNA, providing an additional readout. Both the culture supernatants containing the expressed AMP-CSB fusions and the purified nanoparticles displayed preserved antimicrobial activity in these assays, indicating that the peptides had not lost their membrane-disrupting potency by being locked into the nanoparticle format.

The significance of that last point is hard to overstate. One of the recurring fears in fusion-based production of antimicrobial peptides is that burying the active sequence inside a larger protein or a supramolecular structure will neutralize it, forcing researchers to choose between yield and activity. This study suggests the trade-off can be avoided: the CSB scaffold protects the yeast during production, assembles into defined nanoparticles after purification, and still leaves the antimicrobial function intact enough to compromise E. coli membranes. The authors are careful to frame the activity data as preliminary, and fluorescence-based membrane assays are a first screening step rather than a full pharmacological characterization, but the proof of concept is complete across the whole chain from gene to functional nanoparticle.

The broader context makes the work timely. As multidrug-resistant infections continue to spread, the pipeline for new antibiotics remains thin, and antimicrobial peptides are among the few candidate classes moving from academic labs toward clinical and agricultural applications. What has been missing, in many cases, is a manufacturing route that is scalable, economical, and compatible with the biological activity of the product. Yeast fermentation in Pichia pastoris is already used industrially for enzymes, vaccines, and biopharmaceuticals, so demonstrating that AMP-nanoparticle fusions can be produced there, with yields improved by simple and transferable fermentation parameters, lowers a significant barrier. The finding that high pre-induction biomass and acidic culture conditions around pH 3 boost production is the kind of process knowledge that can be directly adopted by other groups working on similar constructs.

There is also a nanotechnology dimension that extends beyond antibiotics. The CSB triblock polypeptide belongs to a growing family of genetically encoded, self-assembling protein building blocks that can form nanoparticles of controlled shape and size without chemical crosslinkers. Fusing functional peptides to such scaffolds turns the nanoparticles into programmable multivalent display platforms, with potential uses in drug delivery, vaccination, biosensing, and materials science. By showing that the identity of the fused peptide changes the assembly morphology, from rods to globules, the Mexican team has added a data point to the emerging design rules for these systems. The study, which was supported by UNAM-PAPIIT funding and carried out within a doctoral program spanning UNAM and the University of Groningen, establishes key parameters for efficient production of self-assembling AMP-based protein nanoparticles in Pichia pastoris and provides a scalable platform for their further development and functional characterization. If subsequent work confirms and extends the antimicrobial findings to other pathogens, the humble yeast tank could become an unexpected factory for the next generation of nanostructured antibiotics.

Subject of Research: Recombinant production of antimicrobial peptide nanoparticles in Pichia pastoris

Article Title: Production of antimicrobial peptides fused to a nanoparticle-forming polypeptide using Pichia pastoris

Article References: Sanchez-Rueda, E. G., Cruz-Garcia, B. B., Hernandez-Cortes, F. O., Trejo-Perez, M. A., Valentinotti-Bonardi, L., Clairin-Savage, A., Ramírez-Carreto, S., & Hernandez-Garcia, A. (2026). Production of antimicrobial peptides fused to a nanoparticle-forming polypeptide using Pichia pastoris. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14033-3

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14033-3

Keywords: antimicrobial peptides, Pichia pastoris, nanoparticles, self-assembly, recombinant protein production, aurein 1.2, myxinidin, antibiotic resistance, biotechnology, fermentation optimization, atomic force microscopy, E. coli

The research, led by Thanyaporn Tengsuttiwat, Howbeer Muhamadali, and Royston Goodacre at the University of Liverpool, together with colleagues at Aberystwyth University and Thailand’s National Center for Genetic Engineering and Biotechnology, focused on a classic model system: seven strains of E. coli N4830-1 engineered to produce cytochrome b5, a small heme-containing protein that turns the bacteria visibly pink when expressed. The strains, designated N0 through N6, carry between zero and six copies of the cyt b5 gene on plasmids under the control of a temperature-sensitive lambda PL promoter. At 30 degrees Celsius the promoter remains silent, but shifting the culture to 38.5 degrees Celsius releases the lambda cI857 repressor and switches on production synchronously across the entire population, without the need for chemical inducers.

To interrogate the metabolic consequences of this induction, the team employed gas chromatography coupled with mass spectrometry, or GC-MS, an analytical technique prized for its sensitivity and its coverage of central carbon and nitrogen metabolism. Bacterial cultures were rapidly quenched with pre-chilled methanol to freeze metabolism in place, intracellular metabolites were extracted through freeze-thaw cycling, and the dried extracts were chemically derivatised to make them volatile enough for GC analysis. The instrument, an Agilent 8890 GC fitted with a quadrupole time-of-flight mass spectrometer, generated raw data on 861 metabolic features, which the researchers rigorously curated down to 340 high-quality features using internal standards, pooled quality controls, and strict filtering criteria based on reproducibility and chromatographic peak shape.

The statistical treatment was equally careful. Principal component analysis, a chemometric method that compresses thousands of measurements into a few interpretable axes, cleanly separated induced from non-induced cultures along the first principal component, which alone explained more than 41 percent of the total variance. A semi-supervised extension called principal component discriminant function analysis then revealed something striking: among the induced samples, the metabolic profiles arranged themselves along a trajectory that tracked the gene copy number, from strain N0 to N6, even though the algorithm had never been told the ordering. The trend was not perfectly linear, however, hinting that regulatory constraints and adaptive stress responses, rather than gene dosage alone, shape the metabolic landscape during production.

Mapping the significant metabolites onto known E. coli pathways exposed the energetic heart of the burden. Metabolites of the tricarboxylic acid cycle, including citrate, isocitrate, fumarate, and oxaloacetate, together with glycolytic intermediates such as pyruvate, lactate, and 3-phosphoglycerate, were all significantly depleted in the cytochrome b5-producing strains. The pentose phosphate pathway and the glyoxylate shunt showed parallel depletions. The authors interpret this pattern as evidence of a substantially elevated demand for ATP, the universal cellular energy currency, consistent with earlier reports that glycolytic flux in E. coli is tightly controlled by the cell’s energy requirements and that recombinant protein synthesis drives increased flux through energy-generating pathways.

One particularly telling observation involved nicotinamide, a precursor of the essential redox cofactor NAD. Its concentration declined progressively with increasing cyt b5 gene copy number across strains N0 to N4, and tryptophan, from which nicotinamide can be biosynthesised, also shifted significantly between conditions. This suggests that the cofactor supply system itself was being drawn upon to support the redox demands of recombinant expression, providing a potential metabolic bottleneck that strain engineers could target.

The study also documented how the bacteria remodel their membranes and cell walls in response to the double insult of heat induction and protein overproduction. Glycerol, glycerol-3-phosphate, ethanolamine, and O-phosphoethanolamine, all intermediates in phospholipid biosynthesis, changed significantly, as did several unsaturated fatty acids including oleic acid, elaidic acid, and palmitoleic acid, which decreased under induction. N-acetylglucosamine, a building block of the bacterial cell wall, was markedly reduced. These changes echo the well-known homeoviscous adaptation by which bacteria adjust membrane lipid composition to maintain fluidity at elevated temperatures, and they indicate that the cell envelope is a major site of metabolic reconfiguration during recombinant production.

Stress responses left equally clear fingerprints. The polyamines putrescine, cadaverine, and spermidine, compounds known to accumulate under heat, osmotic, oxidative, and ultraviolet stress, were all detected, with putrescine declining while cadaverine and its catabolic derivative 5-aminovaleric acid rose under induction. Alterations in purine and pyrimidine metabolites, including hypoxanthine, thymine, 5,6-dihydrouracil, and orotic acid, pointed to impacts on nucleotide biosynthesis, while changes in glutamine, glutamate, serine, and tryptamine reflected pressure on amino acid pools. Because the experimental design included a control strain carrying the plasmid backbone but no cyt b5 gene, the team could partially disentangle the effects of the 8.5-degree temperature shift itself from those of protein production, concluding that heat induction is the dominant driver of metabolic reprogramming, with gene copy number modulating specific features on top of that response.

The authors are candid about the limitations of their untargeted approach. Absolute quantification was not possible, and the absence of a dedicated washing step means some detected compounds may have originated from the nutrient-rich LB medium rather than from endogenous synthesis. They propose that future work combine intracellular metabolic profiling with metabolic footprinting, lipidomics, targeted quantitative assays, adenylate energy charge measurements, and 13C-based fluxomics to fully characterise the burden and pinpoint bottlenecks. Even so, the findings demonstrate that cytochrome b5 production triggers coordinated adjustments across energy metabolism, cell envelope biosynthesis, nucleotide metabolism, and stress responses. As the global recombinant protein market, valued at roughly 3.25 billion US dollars in 2024, is projected to approach 8.66 billion by 2034, understanding these hidden metabolic costs at pathway level offers a practical roadmap for engineering bacterial hosts and culture conditions that deliver more protein per cell, with less waste of the cell’s own precious energy.

Subject of Research: GC-MS metabolic profiling of recombinant cytochrome b5 production and its metabolic burden in E. coli N4830-1

Article Title: Metabolic profiling analysis of cytochrome b5 production in E. coli N4830-1 using GC-MS

Article References: Metabolic profiling analysis of cytochrome b5 production in E. coli N4830-1 using GC-MS. (n.d.). https://doi.org/10.1007/s11306-026-02522-5

Image Credits: AI Generated

DOI: 10.1007/s11306-026-02522-5

Keywords: metabolomics, GC-MS, E. coli, cytochrome b5, recombinant protein production, metabolic burden, TCA cycle, chemometrics, membrane remodeling, stress response, biotechnology, Metabolomics journal